Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.
- DOI
- 10.1016/j.omton.2026.201229
- Published
- 2026 Jun 18
- Container
- Molecular therapy. Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.omton.2026.201229,
title = {Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.},
author = {Radic-Sarikas B and Markovic M and Zylka MM and Sturtzel C and Ilg M and Surdez D and Metzelder M and Distel M and Ovsianikov A and Halbritter F and Kovar H},
year = {2026},
journal = {Molecular therapy. Oncology},
doi = {10.1016/j.omton.2026.201229},
url = {https://doi.org/10.1016/j.omton.2026.201229}
}RIS
TY - JOUR TI - Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition. AU - Radic-Sarikas B AU - Markovic M AU - Zylka MM AU - Sturtzel C AU - Ilg M AU - Surdez D AU - Metzelder M AU - Distel M AU - Ovsianikov A AU - Halbritter F AU - Kovar H PY - 2026 JO - Molecular therapy. Oncology DO - 10.1016/j.omton.2026.201229 UR - https://doi.org/10.1016/j.omton.2026.201229 ER -
APA
B, R., M, M., MM, Z., C, S., M, I., D, S., M, M., M, D., A, O., F, H., & H, K. (2026). Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.. Molecular therapy. Oncology. https://doi.org/10.1016/j.omton.2026.201229
Source records
- pubmed · retrieved 2026-09-26T22:58:18.122Z
- europe-pmc · retrieved 2026-09-26T22:58:18.148Z